Five journals published by BioMed Central received their first impact factors this year. BMC Bioinformatics, with an impact factor of 5.42, has reinforced its reputation as one of the top journals in its field. Launched in 2000, it is the second highest ranked bioinformatics journal, and already has an impact factor comparable to that of Bioinformatics (5.74), the most established journal in the field, which has been publishing for more than two decades and is supported by a major society.
BMC Genomics enters the Journal Citation Report with a respectable 3.25. This puts it in the top third of the genetics titles, and the top 20% of biotechnology journals. BMC Molecular Biology has an impact factor of 3.12, and BMC Musculoskeletal Disorders an impact factor of 1.00, putting it in the top half of the orthopaedics listing. BMC Genetics has an impact factor of 0.92.
Critical Care's impact factor jumped from 1.9 to 3.21, and the journal is now third in the critical care medicine field having leap-frogged the competitor title Intensive Care Medicine, the official journal of the major European society. Breast Cancer Research also increased it's impact factor from 2.93 to 2.98 and remains the second highest ranking breast cancer journal. Arthritis Research & Therapy maintains its rank of second in the rheumatology field with an impact factor of 4.55.
A number of other journal published by BioMed Central also saw their impact factors and rankings improv e. BMC Infectious Diseases jumped from 1.25 to 2.07. BMC Cell Biology, with an impact factor of 2.62, is now in the top half of the cell biology listing. The impact factor for BMC Health Services Research almost doubled, from 0.68 to 1.23. BMC Cancer went up from 1.70 to 2.29 and BMC Public Health now has an impact factor of 1.55. With an impact factor of 4.03, Respiratory Research is the fifth most cited journal in the highly competitive respirology field.
The impact factors, which are calculated by ISI, look at citations in 2004 of articles published in the journals in the period 2002-2003. According to Dr Matthew Cockerill, Director of Operations at BioMed Central, "These latest impact factors show that BioMed Central's Open Access journals have joined the mainstream of science publishing, and can compete with traditional journals on their own terms. The impact factors also demonstrate one of the key benefits that Open Access offers authors: high visibility and, as a result, a high rate of citation."